A randomised evaluation of low‐dose Ara‐C plus pegylated recombinant arginase BCT‐100 versus low dose Ara‐C in older unfit patients with acute myeloid leukaemia: Results from the LI‐1 trial
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Haematology"
DOI: 10.1111/bjh.18560
Abstract: The survival of acute myeloid leukaemia (AML) patients aged over 60 has been suboptimal historically, whether they are treated using hypomethylating agents, low‐dose cytarabine (LDAC) or venetoclax‐based regimens. Progress is being made, however, for subgroups… read more here.
Keywords: dose ara; ldac; low dose; bct 100 ... See more keywords
Growth suppressive effect of pegylated arginase in malignant pleural mesothelioma xenografts
Sign Up to like & getrecommendations! Published in 2017 at "Respiratory Research"
DOI: 10.1186/s12931-017-0564-3
Abstract: BackgroundMalignant pleural mesothelioma (MPM) is a difficult-to-treat global disease. Pegylated arginase (BCT-100) has recently shown anti-tumor effects in hepatocellular carcinoma, acute myeloid leukemia and melanoma. This study aims to investigate the effects of PEG-BCT-100 in… read more here.
Keywords: mesothelioma; pleural mesothelioma; bct 100; h226 ... See more keywords